SGRY

Business Context and Reporting Period

Company: Surgery Partners, Inc. (SGRY)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2025
Business Overview: The Company owns and operates a national network of 164 surgical facilities (145 Ambulatory Surgery Centers and 19 surgical hospitals) across 30 states, primarily in partnership with physicians. As of March 31, 2025, the Company consolidated 118 facilities for financial reporting purposes.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 8.2% year-over-year, driven by a 5.2% increase in days-adjusted same-facility revenues and net acquisitions. Same-facility case volumes rose 6.5%, offset by a 1.2% decrease in revenue per case.
• Profitability Decline: Operating income decreased 18.6% to $61.9 million. Net loss attributable to the Company widened significantly to $37.7 million from $12.4 million, primarily due to higher interest expense and transaction costs.
• Expense Increases:
  • Interest Expense: Rose 31.5% to $62.2 million due to increased borrowings on the Revolver and financing activities related to senior unsecured notes.
  • Transaction Costs: Increased to $24.7 million from $17.4 million, driven by severance, IT implementation, and revenue cycle standardization.
  • Disposals: A net loss of $6.4 million was recorded on disposals, consolidations, and deconsolidations, compared to $1.5 million in the prior year.
• Cash Flow: Operating cash flow decreased $34.7 million to $6.0 million, attributed to lower net income and changes in operating assets and liabilities.

Guidance, Outlook, and Risks

Management Commentary: Management continues to focus on same-facility performance, selective acquisitions, and portfolio management. Adjusted EBITDA grew 6.6% to $103.9 million, reflecting revenue growth and cost management initiatives.

Acquisitions and Divestitures: In Q1 2025, the Company acquired a controlling interest in four surgical facilities and one physician practice for $44.0 million. It also sold interests in three facilities, resulting in a net loss on deconsolidation of $3.0 million for one facility and a gain of $0.5 million for two others.

Liquidity: The Company maintains $229.3 million in cash and $388.9 million in revolver availability. Management believes current resources are adequate for short- and long-term needs.

Risks and Contingencies:

• Interest Rate Risk: The Company utilizes interest rate swaps and caps to manage exposure. Three swaps and two caps matured in Q1 2025, replaced by deferred premium caps.
• Regulatory and Payor Mix: Risks include potential reductions in government payments, changes in managed care contracts, and regulatory reforms affecting surgical facility operations.
• Legal Proceedings: The Company is subject to ordinary course claims (patient treatment, employment, etc.) but does not anticipate material adverse effects from current proceedings.

Investor Verification Checklist

• Debt Servicing: Verify the impact of rising interest rates on future cash flows given the $3.55 billion total debt load and $62.2 million quarterly interest expense.
• Non-GAAP Reconciliation: Review the reconciliation of Adjusted EBITDA ($103.9 million) to Net Loss ($(37.7) million) to understand the magnitude of non-cash and one-time adjustments.
• Same-Facility Trends: Monitor the divergence between rising case volumes (+6.5%) and declining revenue per case (-1.2%) to assess pricing power and payor mix shifts.
• Transaction Costs: Assess the sustainability of $24.7 million in quarterly transaction and integration costs and their impact on future operating margins.
• Non-Controlling Interests: Note that $37.4 million of net income was attributable to non-controlling interests, significantly impacting the net loss attributable to common shareholders.